Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Tumour hypoxia is a major cause of treatment failure for a variety of malignancies. However, tumour hypoxia also offers treatment opportunities, exemplified by the development compounds that target hypoxic regions within tumours. TH-302 is a pro-drug created by the conjugation of 2-nitroimidazole to bromo-isophosphoramide (Br-IPM). When TH-302 is delivered to regions of hypoxia, Br-IPM, the DNA cross linking toxin, is released. In this study we assessed the cytotoxic activity of TH-302 against osteosarcoma cells in vitro and evaluated its anticancer efficacy as a single agent, and in combination with doxorubicin, in an orthotopic mouse model of human osteosarcoma (OS). In vitro, TH-302 was potently cytotoxic to osteosarcoma cells selectively under hypoxic conditions, whereas primary normal human osteoblasts were protected. Animals transplanted with OS cells directly into their tibiae and left untreated developed mixed osteolytic/osteosclerotic bone lesions and subsequently developed lung metastases. TH-302 reduced tumor burden in bone and cooperated with doxorubicin to protect bone from osteosarcoma induced bone destruction, while it also reduced lung metastases. TH-302 may therefore be an attractive therapeutic agent with strong activity as a single agent and in combination with chemotherapy against OS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia
Carreau, A., Hafny‐Rahbi, B. E., Matejuk, A., Grillon, C., & Kieda, C. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01258.x · Cited by 1,246
Brahimi-Horn, M. C., Chiche, J., & Pouysségur, J. (2007) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0281-3 · Cited by 765 · cited 1×
“Unlike soft tissue tumors, cancer cells in bone are adapted to survive and grow in a microenvironment, which is already hypoxic [28].”
Liu, Q., Sun, J. D., Wang, J., Ahluwalia, D., Baker, A. F., Cranmer, L. D., Ferraro, D., Wang, Y., Duan, J.-X., Ammons, W. S., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1852-8 · Cited by 113
Cited by
Bone Microenvironment and Osteosarcoma Metastasis
Yang, C., Tian, Y., Zhao, F., Chen, Z., Su, P., Li, Y., & Qian, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21196985 · Cited by 291
Hypoxia-responsive nanoparticle based drug delivery systems in cancer therapy: An up-to-date review
Kumari, R., Sunil, D., & Ningthoujam, R. S. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.041 · Cited by 263
Voissiere, A., Jouberton, E., Maubert, E., Degoul, F., Peyrode, C., Chezal, J.-M., & Miot-Noirault, É. (2017) · PLOS ONE · doi:10.1371/journal.pone.0181340 · Cited by 49
Perspectives on Hypoxia Signaling in Tumor Stroma
Zhang, Y., Coleman, M., & Brekken, R. A. (2021) · Cancers · doi:10.3390/cancers13123070 · Cited by 39
Haynes, J., McKee, T. D., Haller, A., Wang, Y., Leung, C., Gendoo, D. M. A., Lima-Fernandes, E., Kreso, A., Wolman, R., Szentgyorgyi, E., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1715 · Cited by 22
“In these studies, the antitumor activity of cisplatin (26), docetaxol (26), doxorubicin (26, 28, 29), irinotecan (26), gemcitabine (26, 41), and temozolomide (26) was increased when combinedwith evofosfamide inmost cancermodels tested.”
Background
Metadata
- Authors
- Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., DeNichilo, M., Ingman, W., Atkins, G. J., Findlay, D. M., Zannettino, A. C. W., & Evdokiou, A.
- Venue
- Cancer Letters
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 357
- Issue
- 1
- Pages
- 160-169
- ISSN
- 0304-3835 (ISSN-L)
- OpenAlex
- W1994950221
- Cited by
- 56
- References
- 3
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. https://app.cochat.ai/papers/10.1016/j.canlet.2014.11.020
- The paper
- Liapis, V., Labrinidis, A., Zinonos, I., Hay, S., Ponomarev, V., Panagopoulos, V., DeNichilo, M., Ingman, W., Atkins, G. J., Findlay, D. M., Zannettino, A. C. W., & Evdokiou, A. (2015). Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. Cancer Letters. https://doi.org/10.1016/j.canlet.2014.11.020
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.